tility of central venous-arterial pCO2 difference as a prognostic marker for clinical outcomes in Transcatheter Aortic Valve Implantation (TAVI)

Recruiting

• Conditions: ranscatheter Aortic Valve Implantation, I35.0: Aortenklappenstenose, OPS-Code 5-35a.01OPS: 5-35a.01; I35.0; Aortic (valve) stenosis

• Registration Number: DRKS00033047
• Lead Sponsor: niklinikum Aachen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

TAVI procedure due to aortic valve stenosis
Indwelling intra-arterial catheter in place (obligatory)
Superior vena cava catheter (internal jugular or subclavian) in place (obligatory).

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28 days mortality

Secondary Outcome Measures

Name	Time	Method
length of hospital and ICU stay, dosage of vasopressors, complications (invasive mechanical ventilation during ICU stay, death at ICU, left heart failure)